Which medication is a JAK inhibitor used in PV?

Which medication is a JAK inhibitor used in PV?

• A. Ruxolitinib
• B. Hydroxyurea
• C. Interferon-alpha
• D. Allopurinol

Answer: (A)

Polycythemia vera involves constitutive JAK-STAT signaling driven by a JAK2 mutation, leading to unchecked red blood cell production and symptoms like splenomegaly and thrombosis risk. Targeting this pathway with a JAK inhibitor directly dampens the abnormal signaling that drives the disease. Ruxolitinib inhibits JAK1 and JAK2, reducing hematocrit, controlling symptoms, and shrinking splenomegaly, especially in patients who are resistant or intolerant to hydroxyurea. This makes it the best option among the choices for PV because it directly addresses the underlying signaling abnormality rather than just reducing cell counts through general cytoreduction. Hydroxyurea and interferon-alpha are cytoreductive therapies that decrease cell production without specifically blocking JAK-STAT signaling. Allopurinol helps manage uric acid but doesn’t affect the myeloproliferation in PV.

Polycythemia vera involves constitutive JAK-STAT signaling driven by a JAK2 mutation, leading to unchecked red blood cell production and symptoms like splenomegaly and thrombosis risk. Targeting this pathway with a JAK inhibitor directly dampens the abnormal signaling that drives the disease. Ruxolitinib inhibits JAK1 and JAK2, reducing hematocrit, controlling symptoms, and shrinking splenomegaly, especially in patients who are resistant or intolerant to hydroxyurea. This makes it the best option among the choices for PV because it directly addresses the underlying signaling abnormality rather than just reducing cell counts through general cytoreduction.

Hydroxyurea and interferon-alpha are cytoreductive therapies that decrease cell production without specifically blocking JAK-STAT signaling. Allopurinol helps manage uric acid but doesn’t affect the myeloproliferation in PV.